Novo Nordisk Shares Jump 6% as Wegovy Fuels Double-Digit Growth
First-quarter revenue rose 19% year-over-year, bolstered by a 21% increase in sales of diabetes and obesity care products. Wegovy, a key GLP-1 therapy, posted an 83% surge in global sales, while U.S. revenue grew 20% as the company anticipated improved supply in the second half of 2025, with compounded GLP-1 drugs being phased out.
However, despite strong growth, Wegovy sales missed expectations, prompting the company to lower its full-year 2025 guidance. Novo Nordisk now expects sales to increase 13% to 21% for the year, down from a prior forecast of 18% to 26%. It also cut its operating profit growth forecast to 16% to 24% at constant exchange rates, down from an earlier estimate of 19% to 27%, citing slower-than-expected uptake of branded GLP-1 drugs in the U.S.
The company also noted that currency effects could reduce reported growth by 3 to 5 percentage points, reflecting ongoing exchange rate volatility.
Is Nova Nordisk a Buy After Earnings?
Novo Nordisk Shares Jump 6% as Wegovy Fuels Double-Digit Growth
Based on the one year price targets offered by 9 analysts, the average target price for Novo Nordisk AS is $95.44 with a high estimate of $127.32 and a low estimate of $63.96. The average target implies a upside of +43.97% from the current price of $66.29.
Based on GuruFocus estimates, the GF Value for Novo Nordisk in one year is projected to be $158.09, implying a substantial upside of 138.48% from the current price of $66.29.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Birkenstock profit beats estimates as shoemaker outlines plan to cope with tariffs
- Birkenstock (NYSE:BIRK) has posted better-than-anticipated profit in its fiscal third quarter and backed its full-year outlook, as the legacy German shoemaker said it is in a good spot despite the impact of elevated U.S. tariffs on the European Union. Known for its sandals and clogs, the more than 250-year old Birkenstock said it is "well-positioned" to handle President Donald Trump's increased 15% levies on many EU products sent to the U.S. -- a rate agreed upon by Washington and Brussels in late July. In a statement, CEO Oliver Reichert said the company will look to mitigate the duties through "a combination of pricing adjustment, cost discipline and inventory management." The firm backed its prior guidance for annual adjusted earnings before interest, taxes, depreciation and amortization margin of 31.3% to 31.8%. Analysts had seen the figure at 31.5%. At constant currency, revenue growth is also tipped to be at the "high end" of its predicted range of 15% to 17%. Operating profit in the three months ended on June 30 rose by 27% versus a year ago to 198 million euros, exceeding Bloomberg consensus projections of 182.7 million euros, with Reichert noting that income was bolstered by mid-single-digit expansion in average selling prices. Meanwhile, quarterly revenue increased by 12% to 635 million euros, compared with estimates of 636.3 million, as an uptick in business-to-business sales was offset by weaker-than-expected demand in the Americas region and at its direct-to-consumer segment. Shares of Birkenstock climbed by more than 3% in premarket U.S. trading on Thursday. Related articles Birkenstock profit beats estimates as shoemaker outlines plan to cope with tariffs If Powell goes, does Fed trust go with him? 7 Undervalued Stocks on the Rise With 50%+ Upside Potential Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
9 minutes ago
- Business Wire
KLC INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against KinderCare Learning Companies, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of KinderCare Learning Companies, Inc. (NYSE: KLC) common stock in or traceable to KinderCare's October 2024 initial public offering ('IPO'), have until October 13, 2025 to seek appointment as lead plaintiff of the KinderCare class action lawsuit. Captioned Gollapalli v. KinderCare Learning Companies, Inc., No. 25-cv-01424 (D. Or.), the KinderCare class action lawsuit charges KinderCare and certain of KinderCare's top executives and directors, KinderCare's controlling shareholder, and the underwriters of the IPO with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of the KinderCare class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@ CASE ALLEGATIONS: KinderCare provides early education and child care services in the United States. In the IPO, KinderCare sold over 27 million shares of common stock to investors at $24 per share, raising $648 million in gross offering proceeds. The KinderCare class action lawsuit alleges that the registration statement for the IPO was false and/or misleading and/or failed to disclose that: (i) numerous incidents of child abuse, neglect, and harm had occurred at KinderCare facilities; (ii) KinderCare did not provide the 'highest quality care possible' at its facilities, and, indeed, in numerous instances had failed to provide even basic care, meet minimum standards in the child care industry, or comply with the laws and regulations governing the care of children; and (iii) as a result, KinderCare was exposed to a material, undisclosed risk of lawsuits, adverse regulatory action, negative publicity, reputational damage, and business loss. Since the IPO, the price of KinderCare stock fell to lows near $9 per share. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased KinderCare common stock in or traceable to the IPO to seek appointment as lead plaintiff in the KinderCare class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the KinderCare class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the KinderCare class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the KinderCare class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Yahoo
18 minutes ago
- Yahoo
Why Vistra Stock Surged Almost 5% Higher on Tuesday
Key Points A pair of Vistra bulls published new takes on the company. These featured price target raises. 10 stocks we like better than Vistra › Electric utility Vistra (NYSE: VST) demonstrated some impressive power as a stock on Tuesday. The company's shares enjoyed a nearly 5% increase in price on the back of two price target increases from market professionals following the company's earnings release last week. That jump was well higher than the 1.1% rise of the S&P 500 index on the day. Two bulls go nuclear Both of the raising analysts are Vistra bulls, as evidenced by the fact that they maintained their respective equivalents of a buy recommendation. The first, Bank of America Securities's Ross Fowler, now believes Vistra could rise to $220 per share. That's up from his preceding level of $214. His peer James Thalacker of BMO Capital made a more dramatic raise, hiking his fair-value assessment to $229 per share from $191. According to reports, both analysts cited the second-quarter results Vistra posted last week as a key factor in their adjustments. Thalacker also pointed out that, per management's comments, there has been much interest in the operations of one of its nuclear power plants, Comanche Peak in Texas. Nuclear enjoys significant support from the Trump administration. In July 2024, Vistra received approval from the government's Nuclear Regulatory Commission to keep operating the plant through 2053. The second-quarter situation That second-quarter release featured some rather encouraging dynamics. For example, Vistra's operating revenue saw a nearly 11% year-over-year rise to $4.25 billion, although its GAAP net income fell to $327 million from the year-ago profit of $467 million. Should you invest $1,000 in Vistra right now? Before you buy stock in Vistra, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Vistra wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Bank of America is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Vistra Stock Surged Almost 5% Higher on Tuesday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
